Other Inhibitors
Learn MoreCETP inhibitors are a class of pharmaceutical compounds that have shown great promise in the field of cardiovascular medicine CETP or Cholesteryl Ester Transfer Protein is a protein responsible for facilitating the transfer of cholesterol between lipoproteins in the bloodstream By inhibiting the activity of CETP these inhibitors have the potential to raise levels of high-density lipoprotein (HDL) cholesterol also known as "good" cholesterol while simultaneously reducing levels of low-density lipoprotein (LDL) cholesterol or "bad" cholesterol This dual effect makes CETP inhibitors a valuable therapeutic option for individuals at risk of cardiovascular diseases such as atherosclerosis Our company offers a range of CETP inhibitors that have undergone rigorous testing and have demonstrated efficacy in clinical trials
Catalog Number | Chemical Name | CAS # | Price |
---|---|---|---|
BC-0455 | Sclerotiorin | 549-23-5 | Online Inquiry |
EI-0190 | Anacetrapib | 875446-37-0 | Online Inquiry |
EI-0705 | Dalcetrapib | 211513-37-0 | Online Inquiry |
EI-0847 | Evacetrapib | 1186486-62-3 | Online Inquiry |
CETP inhibitors have a wide range of applications in the field of cardiovascular health These inhibitors work by blocking the activity of the cholesteryl ester transfer protein (CETP) which is involved in the transfer of cholesterol between lipoproteins This mechanism makes CETP inhibitors an effective tool for managing cholesterol levels and reducing the risk of cardiovascular disease
In the realm of pharmaceuticals CETP inhibitors are utilized as an adjunct therapy for patients with high levels of low-density lipoprotein (LDL) cholesterol By inhibiting CETP activity these inhibitors can increase the levels of high-density lipoprotein (HDL) cholesterol also known as "good" cholesterol while reducing LDL cholesterol This balance helps to prevent the buildup of plaque in the arteries ultimately reducing the risk of heart attacks and strokes
Additionally CETP inhibitors have shown promise in the treatment of other conditions related to lipid metabolism such as familial hypercholesterolemia and dyslipidemia These inhibitors can effectively target specific pathways involved in cholesterol processing providing a potential avenue for managing these conditions
In the future ongoing research aims to further explore the potential of CETP inhibitors in improving cardiovascular health This includes investigating their effects on other lipid parameters such as triglyceride levels as well as their potential to reduce inflammation and oxidative stress both of which are implicated in the development and progression of cardiovascular disease Overall CETP inhibitors offer a promising therapeutic approach for managing cholesterol and preventing cardiovascular events
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.